HomeCompareBDSI vs EQR

BDSI vs EQR: Dividend Comparison 2026

BDSI yields 35.78% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BDSI wins by $143.3K in total portfolio value
10 years
BDSI
BDSI
● Live price
35.78%
Share price
$5.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$183.7K
Annual income
$28,272.37
Full BDSI calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — BDSI vs EQR

📍 BDSI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDSIEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDSI + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDSI pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDSI
Annual income on $10K today (after 15% tax)
$3,041.14/yr
After 10yr DRIP, annual income (after tax)
$24,031.51/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, BDSI beats the other by $20,784.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDSI + EQR for your $10,000?

BDSI: 50%EQR: 50%
100% EQR50/50100% BDSI
Portfolio after 10yr
$112.1K
Annual income
$16,045.98/yr
Blended yield
14.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

BDSI
Analyst Ratings
9
Buy
2
Hold
Consensus: Buy
Altman Z
2.8
Piotroski
6/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDSI buys
0
EQR buys
0
No recent congressional trades found for BDSI or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDSIEQR
Forward yield35.78%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$183.7K$40.5K
Annual income after 10y$28,272.37$3,819.61
Total dividends collected$133.5K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: BDSI vs EQR ($10,000, DRIP)

YearBDSI PortfolioBDSI Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$14,278$3,577.82$11,248$547.57+$3.0KBDSI
2$20,051$4,774.15$12,701$666.53+$7.3KBDSI
3$27,721$6,266.08$14,405$814.59+$13.3KBDSI
4$37,758$8,096.12$16,413$999.84+$21.3KBDSI
5$50,707$10,305.96$18,795$1,232.92+$31.9KBDSI
6$67,191$12,934.95$21,639$1,527.95+$45.6KBDSI
7$87,913$16,018.70$25,057$1,903.80+$62.9KBDSI
8$113,655$19,587.81$29,197$2,385.87+$84.5KBDSI
9$145,277$23,666.62$34,250$3,008.70+$111.0KBDSI
10$183,719$28,272.37$40,467$3,819.61+$143.3KBDSI

BDSI vs EQR: Complete Analysis 2026

BDSIStock

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Full BDSI Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this BDSI vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDSI vs SCHDBDSI vs JEPIBDSI vs OBDSI vs KOBDSI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.